UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2028-09-01
Target enrollment:
Participant gender:
Summary
This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in With Relapse/Refractory Autoimmune Diseases.
Phase:
NA
Details
Lead Sponsor:
The Affiliated Hospital of Xuzhou Medical University